Breathlessness, Chest Mucus Accumulation, Low Energy Levels, Mucus Clearance, Respiratory Symptoms
Conditions
Brief summary
This is a randomized, triple-blind, placebo-controlled clinical trial evaluating the effects of the BetterLungs Mullein + Chlorophyll supplement on mucus clearance and respiratory symptoms over 60 days. One hundred adult participants experiencing chest mucus build-up, difficulty clearing mucus, breathlessness, and low energy levels will be enrolled and randomized to either the active supplement or a matched placebo. Participants will take their assigned product once daily in the morning mixed with water and will complete self-reported questionnaires at Baseline, Day 20, Day 40, and Day 60.
Interventions
DIETARY_SUPPLEMENTBetterLungs
50 participants receive the BetterLungs Mullein + Chlorophyll supplement (ingredients: mullein leaf, chlorophyll, vegetable glycerin, purified water) taken once daily in the morning with the first meal of the day; 2 mL (two full droppers) mixed with 8 ounces of water for 60 days
DIETARY_SUPPLEMENTPlacebo
50 participants receive a matched placebo product (ingredients: moss coloring jungle green color, violet color, spirulina, vegetable glycerin, purified water) taken once daily in the morning with the first meal of the day; 2 mL (two full droppers) mixed with 8 ounces of water for 60 days; the taste and appearance of the placebo are matched to the active product
Sponsors
The Better Brand Inc.
Citruslabs
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Be male or female * Be aged 18+ * Anyone experiencing issues regarding all of the following over the past three months: a build-up of chest mucus, difficulty clearing chest mucus, breathlessness, and low energy levels * Anyone who is generally healthy - does not live with any uncontrolled chronic disease * Willing to refrain from taking any products, prescription medications, or supplements that target lung health, mucus, and energy levels during the test period * Willing to maintain your current diet, sleep schedule, and activity level for the duration of the study * Resides in the United States * Not currently partaking in another research study and will not be partaking in any other research study for the next 60 days and at any point during this study's duration * If currently taking prescription medication are willing to discuss it with their physician before participating in this study
Exclusion criteria
* Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including kidney disease, diabetes, cancer, mental health disorders, history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period * Anyone who drinks heavily (i.e. 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men) * Anyone with a copper sensitivity disorder (such as Wilson's disease or copper metabolism disorders) * Anyone with kidney disease * Anyone with diabetes * Anyone with any known allergies or hypersensitivities to any supplement product ingredients * Anyone who is currently pregnant, trying to conceive, or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in mucus clearance | Baseline, Day 20, Day 40, and Day 60 | Self-reported change in mucus clearance assessed via questionnaire |
| Change in respiratory symptoms | Baseline, Day 20, Day 40, and Day 60 | Self-reported change in respiratory symptoms assessed via questionnaire |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in perceived mucus clearance | Baseline, Day 20, Day 40, and Day 60 | Participant-perceived change in mucus clearance assessed via self-reported questionnaire |
| Change in energy levels | Baseline, Day 20, Day 40, and Day 60 | Participant-perceived change in energy levels assessed via self-reported questionnaire |
| Change in shortness of breath | Baseline, Day 20, Day 40, and Day 60 | Participant-perceived change in shortness of breath associated with physical activity assessed via self-reported questionnaire |
| Change in breathing-related anxiety | Baseline, Day 20, Day 40, and Day 60 | Participant-perceived change in breathing-related anxiety assessed via self-reported questionnaire |
| Change in ease of breathing | Baseline, Day 20, Day 40, and Day 60 | Participant-perceived change in ease of breathing assessed via self-reported questionnaire |
| Change in general well-being | Baseline, Day 20, Day 40, and Day 60 | Participant-perceived change in general well-being assessed via self-reported questionnaire |
Countries
United States
Outcome results
None listed